Predictive value of telomerase reverse transcriptase expression in patients with high risk superficial bladder cancer treated with adjuvant BCG immunotherapy
- First Online:
- 96 Downloads
We conducted a prospective study to determine whether expression of telomerase reverse transcriptase (hTERT) is associated with recurrence-free-survival (RFS) or development of invasive disease in patients with high risk superficial bladder cancer (SBC) that received adjuvant BCG immunotherapy.
Thirty patients with high-grade T1 tumors were evaluated. Pre-BCG TURBT and post-BCG specimens were analyzed for hTERT nucleolar expression by immunohistochemistry.
Post-BCG hTERT expression was statistically significantly lower than pre-BCG hTERT expression. Pre-BCG hTERT nucleolar staining in more than 75% of cells was associated with worse RFS (9 months vs. not yet reached, P = 0.05), while post-BCG hTERT nucleolar staining in more than 50% of the cells was associated with worse RFS (6 months vs. not yet reached, P = 0.001) and development of invasive disease. In multivariate analysis, post-BCG hTERT expression was independently associated with RFS and development of invasive disease.
Immunohistochemical evaluation of hTERT may help define a subset of high risk SBC patients that will eventually fail BCG and may therefore benefit from early salvage cystectomy.
KeywordsSuperficial bladder cancer Telomerase reverse transcriptase BCG Recurrence Multivariate analysis
- Dalerba P, Guiducci C, Poliani PL et al (2005) Reconstitution of human telomerase reverse transcriptase expression rescues colorectal carcinoma cells from in vitro senescence: evidence against immortality as a constitutive trait of tumor cells. Cancer Res 65:2321–2329. doi:10.1158/0008-5472.CAN-04-3678 PubMedCrossRefGoogle Scholar
- Domont J, Pawlik TM, Boige V et al (2005) Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis. J Clin Oncol 23:3086–3093. doi:10.1200/JCO.2005.06.944 PubMedCrossRefGoogle Scholar
- Saint F, Salomon L, Quintela R et al (2003) Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol 43:351–360. doi:10.1016/S0302-2838(03)00048-4 (discussion 360–361)PubMedCrossRefGoogle Scholar
- Smith DL, Soria JC, Morat L et al (2004) Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 11:45–51. doi:10.1007/BF02524345 PubMedCrossRefGoogle Scholar
- Van Der Meijden A, Sylvester R, Collette L et al (2000) The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 164:1533–1537. doi:10.1016/S0022-5347(05)67022-X CrossRefGoogle Scholar
- Zlotta AR, Noel JC, Fayt I et al (1999) Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guerin intravesical therapy. J Urol 161:792–798. doi:10.1016/S0022-5347(01)61770-1 PubMedCrossRefGoogle Scholar